Header Logo

NAIFA L BUSAIDY

TitleAssociate Professor
InstitutionMD Anderson
DepartmentEndocrine Neoplasia & HD
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hamidi S, Yedururi S, Hu MI, Busaidy NL, Sherman SI, Jimenez C, Grubbs EG, Maniakas A, Zafereo ME, Subbiah V, Waguespack SG. Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid. 2024 Dec 04. PMID: 39630530.
      Citations:    Fields:    
    2. Dagher SA, Learned KO, Dagher R, Wang JR, Zhao X, Hosseini SM, Maniakas A, Cabanillas ME, Busaidy NL, Dadu R, Iyer P, Zafereo ME, Khalaf AM. [18F]-Fluorodeoxyglucose Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma Following BRAF-Targeted Therapy. AJNR Am J Neuroradiol. 2024 Nov 21. PMID: 39572200.
      Citations:    Fields:    
    3. Bronk JK, Augustyn A, Mohamed ASR, David Fuller C, Garden AS, Moreno AC, Lee A, Morrison WH, Phan J, Reddy JP, Rosenthal DI, Spiotto MT, Frank SJ, Dadu R, Busaidy N, Zafereo M, Wang JR, Maniakas A, Ferrarotto R, Iyer PC, Cabanillas ME, Gunn GB. Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer. Radiother Oncol. 2024 Nov 01; 202:110602. PMID: 39489425.
      Citations:    Fields:    
    4. Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, Williams MD, Zafereo M, Wang JR, Lu C, Ning M, McKinley BA, Woodman SE, Duose D, Gunn GB, Busaidy NL, Rare Tumor Initiative Team. Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2024 Oct 24. PMID: 39446377; PMCID: PMC11581602.
      Citations:    Fields:    
    5. Hamidi S, Dadu R, Zafereo ME, Ferrarotto R, Wang JR, Maniakas A, Gunn GB, Lee A, Spiotto MT, Iyer PC, Sousa LG, Akhave NS, Ahmed S, Learned KO, Lu C, Lai SY, Williams M, Hosseini SM, Busaidy NL, Cabanillas ME. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol. 2024 Sep 01; 10(9):1264-1271. PMID: 38990526.
      Citations:    Fields:    Translation:Humans
    6. Feldman HA, Busaidy NL, Tame-Elorduy A, Silva AK, Halfteck G, Merriman K, Waguespack SG, Graham PH, Williams MD, Perrier ND. Clinical course of atypical parathyroid neoplasm with soft tissue extension. J Surg Oncol. 2024 Aug 19. PMID: 39155668.
      Citations:    Fields:    
    7. Hensley SG, Hu MI, Bassett RL, Ying AK, Zafereo ME, Perrier ND, Busaidy NL, Hyde SM, Grubbs EG, Waguespack SG, Hensley SG, Hu MI, Bassett RL, Ying AK, Zafereo ME, Perrier ND, Busaidy NL, Hyde SM, Grubbs EG, Waguespack SG. Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-Term Outcomes in 144 Patients Over 6 Decades. J Clin Endocrinol Metab. 2024 Aug 13; 109(9):2256-2268. PMID: 38441533.
      Citations:    Fields:    Translation:Humans
    8. Shirali AS, Hu MI, Chiang YJ, Graham PH, Fisher SB, Sosa JA, Perrier N, Brown S, Holla VR, Dadu R, Busaidy N, Sherman SI, Cabanillas M, Waguespack SG, Zafereo ME, Grubbs EG. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness. J Endocr Soc. 2024 Apr 06; 8(6):bvae048. PMID: 38660141; PMCID: PMC11041404.
      Citations: 3     
    9. Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL, Cabanillas ME. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024 Mar; 34(3):336-346. PMID: 38226606.
      Citations: 4     Fields:    Translation:Humans
    10. Maniakas A, Sullivan A, Hu MI, Busaidy NL, Cabanillas ME, Dadu R, Waguespack SG, Fisher SB, Graham PH, Gross ND, Grubbs EG, Perrier ND, Wang JR, Gunn B, Garden AS, Megahed R, Navuluri S, Li X, Williams MD, Zafereo M. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer. Head Neck. 2024 02; 46(2):328-335. PMID: 38009416.
      Citations:    Fields:    Translation:Humans
    11. Szabo Yamashita T, Shirali AS, Meas S, Sarli V, Clemente-Gutierrez UE, Chiang YJ, Silva-Figueroa A, Vodopivec DM, Williams M, Fisher SB, Graham PH, Grubbs EG, Lucci A, Busaidy N, Perrier ND. Is there a role for liquid biopsy in the surveillance of parathyroid carcinoma? Surgery. 2024 01; 175(1):193-198. PMID: 37993289.
      Citations:    Fields:    Translation:HumansCells
    12. Hamidi S, Hofmann MC, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, Dadu R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol (Lausanne). 2023; 14:1176731. PMID: 37435488; PMCID: PMC10331470.
      Citations: 2     Fields:    Translation:Humans
    13. Lu L, Wang JR, Henderson YC, Bai S, Yang J, Hu M, Shiau CK, Pan T, Yan Y, Tran TM, Li J, Kieser R, Zhao X, Wang J, Nurieva R, Williams MD, Cabanillas ME, Dadu R, Busaidy NL, Zafereo M, Navin N, Lai SY, Gao R. Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics. J Clin Invest. 2023 06 01; 133(11). PMID: 37053016; PMCID: PMC10231997.
      Citations: 3     Fields:    Translation:HumansCells
    14. Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, Learned KO, Chasen NN, Vu T, Maniakas A, Eguia AA, Diersing J, Gross ND, Goepfert R, Lai SY, Hofmann MC, Ferrarotto R, Lu C, Gunn GB, Spiotto MT, Subbiah V, Williams MD, Cabanillas ME, Zafereo ME. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid. 2023 04; 33(4):484-491. PMID: 36762947; PMCID: PMC10122263.
      Citations: 2     Fields:    Translation:Humans
    15. Chen YH, Sperling J, Xu L, Goswami M, Maniakas A, Williams MD, Lai SY, Zafereo ME, Wang JR, Cabanillas M, Busaidy N, Dadu R. Prior Thyroid and Nonthyroid Cancer History Do Not Significantly Alter Overall Survival in Patients Diagnosed with Anaplastic Thyroid Cancer. Thyroid. 2023 03; 33(3):321-329. PMID: 36511380.
      Citations:    Fields:    Translation:Humans
    16. Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol. 2023 Feb 18; 7(1):19. PMID: 36801912; PMCID: PMC9938883.
      Citations:    
    17. Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, Waguespack SG, Wang JR, Maniakas A, Lai SY, Diersing J, Kwon M, Grubbs EG, Subbiah V, Williams MD, Zafereo ME. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid. 2023 01; 33(1):129-132. PMID: 36503246.
      Citations: 2     Fields:    Translation:Humans
    18. Shenson JA, Zafereo ME, Lee M, Contrera KJ, Feng L, Boonsripitayanon M, Gross N, Goepfert R, Maniakas A, Wang JR, Grubbs L, Vaporciyan A, Hofstetter W, Swisher S, Mehran R, Rice D, Sepesi B, Antonoff M, Cabanillas M, Busaidy N, Dadu R, Silver NL. Clinical outcomes of combined cervical and transthoracic surgical approaches in patients with advanced thyroid cancer. Head Neck. 2023 03; 45(3):547-554. PMID: 36524701.
      Citations:    Fields:    Translation:Humans
    19. Cabanillas ME, Busaidy NL, Sherman SI. Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World. Clin Cancer Res. 2022 10 03; 28(19):4164-4166. PMID: 35895318.
      Citations:    Fields:    
    20. Hofmann MC, Kunnimalaiyaan M, Wang JR, Busaidy NL, Sherman SI, Lai SY, Zafereo M, Cabanillas ME. Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers. Endocr Relat Cancer. 2022 11 01; 29(11):R173-R190. PMID: 35975971; PMCID: PMC9534048.
      Citations:    
    21. Wang JR, Montierth M, Xu L, Goswami M, Zhao X, Cote G, Wang W, Iyer P, Dadu R, Busaidy NL, Lai SY, Gross ND, Ferrarotto R, Lu C, Gunn GB, Williams MD, Routbort M, Zafereo ME, Cabanillas ME. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2022 08; 6:e2100504. PMID: 35977347; PMCID: PMC10530586.
      Citations:    
    22. Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 08; 20(8):925-951. PMID: 35948029.
      Citations:    
    23. Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, DeSouza JA, Poi M, Seligson ND, Cabanillas ME, Sipos JA, Ringel MD, Eisfeld AK, Timmers C, Shah MH. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. Thyroid. 2022 Oct; 32(10):1184-1192. PMID: 35658604; PMCID: PMC9595631.
      Citations:    Fields:    
    24. Walgama E, Busaidy N, Zafereo M. Novel Therapeutics and Treatment Strategies for Medullary Thyroid Cancer. Endocrinol Metab Clin North Am. 2022 06; 51(2):379-389. PMID: 35662447.
      Citations:    Fields:    Translation:Humans
    25. Waguespack SG, Tewari SO, Busaidy NL, Zafereo ME. Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion-Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease? JCO Precis Oncol. 2022 04; 6:e2100467. PMID: 35420905; PMCID: PMC9029926.
      Citations:    Fields:    Translation:Humans
    26. Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam F. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep. 2022 01 24; 12(1):1248. PMID: 35075200; PMCID: PMC8786858.
      Citations:    Fields:    Translation:HumansAnimalsCells
    27. Yennurajalingam S, Valero V, Lu Z, Liu DD, Busaidy NL, Reuben JM, Diaz Fleming C, Williams JL, Hess KR, Basen-Engquist K, Bruera E. Combination Therapy of Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Phase II Randomized Double-Blind Controlled Trial. J Natl Compr Canc Netw. 2021 12 29; 20(3):235-243. PMID: 34965510.
      Citations:    Fields:    
    28. Maniakas A, Henderson YC, Hei H, Peng S, Chen Y, Jiang Y, Ji S, Cardenas M, Chiu Y, Bell D, Williams MD, Hofmann MC, Scherer SE, Wheeler DA, Busaidy NL, Dadu R, Wang JR, Cabanillas ME, Zafereo M, Johnson FM, Lai SY. Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity. J Clin Endocrinol Metab. 2021 10 21; 106(11):e4652-e4665. PMID: 34147031; PMCID: PMC8530744.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    29. Bagheri-Yarmand R, Busaidy NL, McBeath E, Danysh BP, Evans KW, Moss TJ, Akcakanat A, Ng PKS, Knippler CM, Golden JA, Williams MD, Multani AS, Cabanillas ME, Shaw KR, Meric-Bernstam F, Shah MH, Ringel MD, Hofmann MC. RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient. Cancers (Basel). 2021 Sep 30; 13(19). PMID: 34638434; PMCID: PMC8507731.
      Citations: 1     
    30. Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, Dadu R. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer. 2021 06 02; 28(7):419-431. PMID: 33890870; PMCID: PMC8183642.
      Citations: 4     Fields:    Translation:Humans
    31. Qin Y, Wang JR, Wang Y, Iyer P, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, Gunn GB, Wei P, Patel K, Hofmann MC, Cabanillas ME. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid. 2021 08; 31(8):1235-1243. PMID: 33599171; PMCID: PMC8420950.
      Citations: 6     Fields:    Translation:Humans
    32. Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas M. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021 01; 43(1):E7-E12. PMID: 33169506; PMCID: PMC7756223.
      Citations: 7     Fields:    Translation:Humans
    33. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open. 2020 10; 5(5):e000799. PMID: 33097651; PMCID: PMC7590373.
      Citations: 10     Translation:HumansCTClinical Trials
    34. Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross ND, Sturgis EM, Goepfert RP, Lai SY, Cabanillas ME, Zafereo M. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol. 2020 09 01; 6(9):1397-1404. PMID: 32761153; PMCID: PMC7411939.
      Citations: 35     Fields:    Translation:Humans
    35. Perrier ND, Arnold A, Costa-Guda J, Busaidy NL, Nguyen H, Chuang HH, Brandi ML. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: New and future perspectives for parathyroid carcinoma. Endocr Relat Cancer. 2020 08; 27(8):T53-T63. PMID: 32449693.
      Citations: 4     Fields:    Translation:Humans
    36. Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC. Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid. 2020 09; 30(9):1288-1296. PMID: 32216548; PMCID: PMC7869871.
      Citations: 18     Fields:    Translation:Humans
    37. Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. 2020 06; 42(6):1325-1328. PMID: 32437031; PMCID: PMC7262055.
      Citations: 11     Fields:    Translation:HumansCellsPHPublic Health
    38. Zafereo M, McIver B, Steward DL, Holsinger FC, Kandil E, Williams M, Cruz F, Loyola S, Solar A, Roa JC, Lobos M, Arias T, Kong CS, Busaidy N, Grubbs EG, Graham P, Stewart J, Tang A, Wang J, Orloff L, Lagos M, Osorio M, Schachter D, Franco C, Medina F, Wohllk N, Arroyo P, Vargas-Salas S, Dom?nguez JM, Le?n A, Droppelman N, Henr?quez M, Diaz RE, Veliz J, Horvath E, Tala H, Pineda P, Vasquez F, Traipe E, Mar?n L, Miranda G, Bruce E, Bracamonte M, Mena N, Gonz?lez HE. A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials. Thyroid. 2020 05; 30(5):704-712. PMID: 31910118; PMCID: PMC7232660.
      Citations: 1     Fields:    Translation:Humans
    39. Busaidy NL. The Year in Medical Thyroidology Review: Current Challenges and Future Directions. Thyroid. 2020 01; 30(1):13-19. PMID: 31842716; PMCID: PMC6983747.
      Citations:    Fields:    Translation:Humans
    40. Silva-Figueroa AM, Bassett R, Christakis I, Moreno P, Clarke CN, Busaidy NL, Grubbs EG, Lee JE, Perrier ND, Williams MD. Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms. Endocr Pathol. 2019 Dec; 30(4):285-296. PMID: 31734935.
      Citations: 5     Fields:    Translation:Humans
    41. Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86. PMID: 31648931.
      Citations: 4     Fields:    Translation:Humans
    42. Gan Q, Edeiken BS, Chen MM, Grubbs EG, Busaidy NL, Zafereo M, Perrier ND, Gule-Monroe MD, Krishnamurthy S. Utility of subcategorization of atypia of undetermined significance/follicular lesion of undetermined significance category in ultrasound-guided thyroid fine-needle aspiration in a large referral cancer center. J Am Soc Cytopathol. 2019 Nov - Dec; 8(6):309-316. PMID: 31526696.
      Citations:    Fields:    Translation:Humans
    43. Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043. PMID: 31319771; PMCID: PMC6707029.
      Citations: 36     Fields:    Translation:Humans
    44. Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. 2019 Aug; 145(8):1977-1986. PMID: 31309300.
      Citations: 6     Fields:    Translation:Humans
    45. Asare EA, Silva-Figueroa A, Hess KR, Busaidy N, Graham PH, Grubbs EG, Lee JE, Williams MD, Perrier ND. Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center. Ann Surg Oncol. 2019 Oct; 26(11):3593-3599. PMID: 31111352.
      Citations: 7     Fields:    Translation:Humans
    46. Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head Neck. 2019 06; 41(6):1928-1934. PMID: 30758123; PMCID: PMC6542589.
      Citations: 6     Fields:    Translation:Humans
    47. Sagiv O, Kandl TJ, Thakar SD, Thuro BA, Busaidy NL, Cabanillas M, Jimenez C, Dadu R, Graham PH, Debnam JM, Esmaeli B. Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients. Ophthalmic Plast Reconstr Surg. 2019 Jan/Feb; 35(1):50-52. PMID: 29927883.
      Citations: 10     Fields:    Translation:Humans
    48. Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BG, Skinner HD, Garden AS, Cabanillas ME, Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BG, Skinner HD, Garden AS, Cabanillas ME. Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2018 Dec; 2. PMID: 35135166; PMCID: PMC9797231.
      Citations: 1     Fields:    
    49. Meltzer CJ, Irish J, Angelos P, Busaidy NL, Davies L, Dwojak S, Ferris RL, Haugen BR, Harrell RM, Haymart MR, McIver B, Mechanick JI, Monteiro E, Morris JC, Morris LGT, Odell M, Scharpf J, Shaha A, Shin JJ, Shonka DC, Thompson GB, Tuttle RM, Urken ML, Wiseman SM, Wong RJ, Randolph G. American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. Head Neck. 2019 04; 41(4):843-856. PMID: 30561068.
      Citations: 2     Fields:    Translation:Humans
    50. Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw. 2018 12; 16(12):1429-1440. PMID: 30545990.
      Citations: 82     Fields:    Translation:Humans
    51. Jaber T, Waguespack SG, Cabanillas ME, Elbanan M, Vu T, Dadu R, Sherman SI, Amit M, Santos EB, Zafereo M, Busaidy NL. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab. 2018 10 01; 103(10):3698-3705. PMID: 30032208; PMCID: PMC6179172.
      Citations: 23     Fields:    Translation:Humans
    52. Tam S, Boonsripitayanon M, Amit M, Fellman BM, Li Y, Busaidy NL, Cabanillas ME, Dadu R, Sherman S, Waguespack SG, Williams MD, Goepfert RP, Gross ND, Perrier ND, Sturgis EM, Zafereo ME. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. Thyroid. 2018 10; 28(10):1301-1310. PMID: 30141373.
      Citations: 35     Fields:    Translation:Humans
    53. Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid. 2018 10; 28(10):1243-1251. PMID: 30132401; PMCID: PMC6157359.
      Citations: 41     Fields:    Translation:Humans
    54. Clarke CN, Katsonis P, Hsu TK, Koire AM, Silva-Figueroa A, Christakis I, Williams MD, Kutahyalioglu M, Kwatampora L, Xi Y, Lee JE, Koptez ES, Busaidy NL, Perrier ND, Lichtarge O. Comprehensive Genomic Characterization of Parathyroid Cancer Identifies Novel Candidate Driver Mutations and Core Pathways. J Endocr Soc. 2019 Mar 01; 3(3):544-559. PMID: 30788456; PMCID: PMC6372985.
      Citations: 17     
    55. Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018 08 01; 29(8):1869-1876. PMID: 29912274; PMCID: PMC6096733.
      Citations: 108     Fields:    Translation:HumansCellsCTClinical Trials
    56. Tam S, Amit M, Boonsripitayanon M, Busaidy NL, Cabanillas ME, Waguespack SG, Gross ND, Grubbs EG, Williams MD, Lai SY, Sturgis EM, Zafereo ME. Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid. 2018 08; 28(8):982-990. PMID: 29936892.
      Citations: 16     Fields:    Translation:Humans
    57. Silva-Figueroa A, Villalobos P, Williams MD, Bassett RL, Clarke CN, Lee JE, Busaidy NL, Perrier ND. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages. Surgery. 2018 11; 164(5):960-964. PMID: 30033186.
      Citations: 2     Fields:    Translation:HumansCells
    58. Amit M, Boonsripitayanon M, Goepfert RP, Tam S, Busaidy NL, Cabanillas ME, Dadu R, Varghese J, Waguespack SG, Gross ND, Graham P, Williams MD, Sturgis EM, Zafereo ME. Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer? Ann Surg Oncol. 2018 Oct; 25(11):3380-3388. PMID: 30022274.
      Citations: 13     Fields:    Translation:Humans
    59. Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018 07 11; 6(1):68. PMID: 29996921; PMCID: PMC6042271.
      Citations: 64     Fields:    Translation:Humans
    60. Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid. 2018 07; 28(7):945-951. PMID: 29742974; PMCID: PMC6425982.
      Citations: 38     Fields:    Translation:Humans
    61. Ferris RL, Nikiforov Y, Terris D, Seethala RR, Ridge JA, Angelos P, Duh QY, Wong R, Sabra MM, Fagin JA, McIver B, Bernet VJ, Harrell RM, Busaidy N, Cibas ES, Faquin WC, Sadow P, Baloch Z, Shindo M, Orloff L, Davies L, Randolph GW. AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Head Neck. 2018 09; 40(9):1881-1888. PMID: 29947030; PMCID: PMC6175359.
      Citations: 14     Fields:    Translation:Humans
    62. Romero Arenas MA, Rich TA, Hyde SM, Busaidy NL, Cote GJ, Hu MI, Gagel RF, Gidley PW, Jimenez C, Kupferman ME, Peterson SK, Sherman SI, Ying A, Bassett RL, Waguespack SG, Perrier ND, Grubbs EG. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402. PMID: 29427212; PMCID: PMC10013431.
      Citations: 6     Fields:    Translation:Humans
    63. Amit M, Tam S, Boonsripitayanon M, Cabanillas ME, Busaidy NL, Grubbs EG, Lai SY, Gross ND, Sturgis EM, Zafereo ME. Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer. JAMA Otolaryngol Head Neck Surg. 2018 02 01; 144(2):108-114. PMID: 29192312; PMCID: PMC5839287.
      Citations: 19     Fields:    Translation:Humans
    64. Cabanillas ME, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL. Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000Res. 2018; 7. PMID: 31583077; PMCID: PMC6753603.
      Citations: 13     Fields:    
    65. Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Lorch JH, Calles A, J?nne PA. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 04 01; 24(7):1546-1553. PMID: 29301825.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    66. Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 01; 28(1):79-87. PMID: 29161986; PMCID: PMC6425981.
      Citations: 37     Fields:    Translation:Humans
    67. Tam S, Amit M, Boonsripitayanon M, Cabanillas ME, Busaidy NL, Gunn GB, Lai SY, Gross ND, Sturgis EM, Zafereo ME. Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer. JAMA Otolaryngol Head Neck Surg. 2017 12 01; 143(12):1244-1251. PMID: 29098272; PMCID: PMC5824297.
      Citations: 9     Fields:    Translation:Humans
    68. Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017 09 01; 102(9):3591-3599. PMID: 28911154; PMCID: PMC5587058.
      Citations: 22     Fields:    Translation:Humans
    69. Duh QY, Busaidy NL, Rahilly-Tierney C, Gharib H, Randolph G. A Systematic Review of the Methods of Diagnostic Accuracy Studies of the Afirma Gene Expression Classifier. Thyroid. 2017 10; 27(10):1215-1222. PMID: 28741442.
      Citations: 5     Fields:    Translation:Humans
    70. Christakis I, Vu T, Chuang HH, Fellman B, Figueroa AMS, Williams MD, Busaidy NL, Perrier ND. The diagnostic accuracy of neck ultrasound, 4D-Computed tomographyand sestamibi imaging in parathyroid carcinoma. Eur J Radiol. 2017 Oct; 95:82-88. PMID: 28987702.
      Citations: 9     Fields:    Translation:Humans
    71. Christakis I, Silva AM, Williams MD, Garden A, Grubbs EG, Busaidy NL, Lee JE, Perrier ND, Zafereo M. Postoperative local-regional radiation therapy in the treatment of parathyroid carcinoma: The MD Anderson experience of 35 years. Pract Radiat Oncol. 2017 Nov - Dec; 7(6):e463-e470. PMID: 28751227.
      Citations: 6     Fields:    Translation:Humans
    72. Cabanillas ME, Williams MD, Gunn GB, Weitzman SP, Burke L, Busaidy NL, Ying AK, Yiin YH, William WN, Lu C, Lai SY. Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head Neck. 2017 07; 39(7):1291-1295. PMID: 28452157.
      Citations: 6     Fields:    Translation:Humans
    73. Silva-Figueroa AM, Hess KR, Williams MD, Clarke CN, Christakis I, Graham PH, Grubbs EG, Lee JE, Busaidy NL, Perrier ND. Prognostic Scoring System to Risk Stratify Parathyroid Carcinoma. J Am Coll Surg. 2017 Mar 15. PMID: 28427885.
      Citations: 8     Fields:    
    74. Ibrahim EY, Busaidy NL. Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer. Curr Opin Oncol. 2017 03; 29(2):151-158. PMID: 28141684.
      Citations: 10     Fields:    Translation:Humans
    75. Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 2017 05; 27(5):672-681. PMID: 28068873; PMCID: PMC5802249.
      Citations: 44     Fields:    Translation:Humans
    76. Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas ME. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 2017 01; 27(1):81-87. PMID: 27785980; PMCID: PMC5704769.
      Citations: 28     Fields:    Translation:Humans
    77. Christakis I, Silva AM, Kwatampora LJ, Warneke CL, Clarke CN, Williams MD, Grubbs EG, Lee JE, Busaidy NL, Perrier ND. Oncologic progress for the treatment of parathyroid carcinoma is needed. J Surg Oncol. 2016 Nov; 114(6):708-713. PMID: 27753088.
      Citations: 6     Fields:    Translation:Humans
    78. Xu JY, Murphy WA, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI, Milton DR. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877. PMID: 27662441; PMCID: PMC5155685.
      Citations: 7     Fields:    Translation:Humans
    79. Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4461-4467. PMID: 27575943; PMCID: PMC5095245.
      Citations: 11     Fields:    Translation:HumansCells
    80. Christakis I, Qiu W, Silva Figueroa AM, Hyde S, Cote GJ, Busaidy NL, Williams M, Grubbs E, Lee JE, Perrier ND. Clinical Features, Treatments, and Outcomes of Patients with Thymic Carcinoids and Multiple Endocrine Neoplasia Type 1 Syndrome at MD Anderson Cancer Center. Horm Cancer. 2016 08; 7(4):279-87. PMID: 27311764; PMCID: PMC10355947.
      Citations: 13     Fields:    Translation:Humans
    81. Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 07; 78(1):167-71. PMID: 27286994.
      Citations: 3     Fields:    Translation:Humans
    82. Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology. 2016; 90(6):339-46. PMID: 27207748; PMCID: PMC4909575.
      Citations: 17     Fields:    Translation:Humans
    83. Christakis I, Busaidy NL, Cote GJ, Williams MD, Hyde SM, Silva Figueroa AM, Kwatampora LJ, Clarke CN, Qiu W, Lee JE, Perrier ND. Parathyroid carcinoma and atypical parathyroid neoplasms in MEN1 patients; A clinico-pathologic challenge. The MD Anderson case series and review of the literature. Int J Surg. 2016 Jul; 31:10-6. PMID: 27212590.
      Citations: 14     Fields:    Translation:Humans
    84. Falchook GS, Rady P, Konopinski JC, Busaidy N, Hess K, Hymes S, Nguyen HP, Prieto VG, Bustinza-Linares E, Lin Q, Parkhurst KL, Hong DS, Sherman S, Tyring SK, Kurzrock R. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Arch Dermatol Res. 2016 Jul; 308(5):357-65. PMID: 27098388.
      Citations: 3     Fields:    Translation:HumansCells
    85. Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw. 2015 Sep; 13(9):1140-50. PMID: 26358798; PMCID: PMC4986600.
      Citations: 49     Fields:    Translation:Humans
    86. Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid. 2015 Oct; 25(10):1085-90. PMID: 26200040; PMCID: PMC4589264.
      Citations: 10     Fields:    Translation:Humans
    87. Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine. 2016 Feb; 51(2):351-9. PMID: 26206754.
      Citations: 8     Fields:    Translation:Humans
    88. Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist. 2015 Jul; 20(7):737-41. PMID: 26054632; PMCID: PMC4492245.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    89. Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015 Jan; 100(1):E77-81. PMID: 25353071; PMCID: PMC4283003.
      Citations: 48     Fields:    Translation:Humans
    90. Grubbs EG, Ng PK, Bui J, Busaidy NL, Chen K, Lee JE, Lu X, Lu H, Meric-Bernstam F, Mills GB, Palmer G, Perrier ND, Scott KL, Shaw KR, Waguespack SG, Williams MD, Yelensky R, Cote GJ. RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab. 2015 Mar; 100(3):788-93. PMID: 25546157; PMCID: PMC4333032.
      Citations: 34     Fields:    Translation:Humans
    91. Brady V, Thosani S, Zhou S, Bassett R, Busaidy NL, Lavis V. Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy. Diabetes Technol Ther. 2014 Dec; 16(12):874-9. PMID: 25321387; PMCID: PMC4241952.
      Citations: 6     Fields:    Translation:Humans
    92. Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M, Jimenez C, Lee JE, Perrier N, Sherman SI, Waguespack SG, Ying A, Grubbs E. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106. PMID: 24617864; PMCID: PMC4080849.
      Citations: 13     Fields:    Translation:Humans
    93. Busaidy N, Erasmus J, Williams MD, Johnson FM, Recondo G. Spindle epithelial tumor with thymus-like differentiation: A case report and comprehensive review of the literature and treatment options. Head Neck. 2015 May; 37(5):746-54. PMID: 24677409.
      Citations: 7     Fields:    Translation:Humans
    94. Holsinger FC, Ramaswamy U, Cabanillas ME, Lang J, Lin HY, Busaidy NL, Grubbs E, Rahim S, Sturgis EM, Lee JE, Weber RS, Clayman GL, Rohren EM. Measuring the extent of total thyroidectomy for differentiated thyroid carcinoma using radioactive iodine imaging: relationship with serum thyroglobulin and clinical outcomes. JAMA Otolaryngol Head Neck Surg. 2014 May; 140(5):410-5. PMID: 24700275.
      Citations: 5     Fields:    Translation:Humans
    95. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82. PMID: 24733667; PMCID: PMC4012968.
      Citations: 12     Fields:    Translation:Humans
    96. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94. PMID: 24628550; PMCID: PMC4037722.
      Citations: 35     Fields:    Translation:Humans
    97. Ganeshan D, Paulson E, Duran C, Cabanillas ME, Busaidy NL, Charnsangavej C. Current update on medullary thyroid carcinoma. AJR Am J Roentgenol. 2013 Dec; 201(6):W867-76. PMID: 24261394.
      Citations: 17     Fields:    Translation:Humans
    98. Vin H, Ching G, Ojeda SS, Adelmann CH, Chitsazzadeh V, Dwyer DW, Ma H, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Ciurea AM, Duvic M, Busaidy NL, Tannir NM, Tsai KY. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Mol Cancer Ther. 2014 Jan; 13(1):221-9. PMID: 24170769; PMCID: PMC4366425.
      Citations: 12     Fields:    Translation:HumansCells
    99. Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro L, Jimenez C, Vassilopoulou-Sellin R, Habra MA. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013 Dec; 169(6):891-899. PMID: 24086089; PMCID: PMC4441210.
      Citations: 90     Fields:    Translation:Humans
    100. Shawa H, Elsayes KM, Javadi S, Morani A, Williams MD, Lee JE, Waguespack SG, Busaidy NL, Vassilopoulou-Sellin R, Jimenez C, Habra MA. Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre. Clin Endocrinol (Oxf). 2014 Mar; 80(3):342-7. PMID: 24033606.
      Citations: 22     Fields:    Translation:Humans
    101. Shawa H, Busaidy NL, Schellingerhout D, Habra MA. Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. BMJ Case Rep. 2013 May 15; 2013. PMID: 23682094; PMCID: PMC3670046.
      Citations:    Fields:    Translation:Humans
    102. Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61. PMID: 23676418.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    103. Lee S, Skelton TS, Zheng F, Schwartz KA, Perrier ND, Lee JE, Bassett RL, Ahmed S, Krishnamurthy S, Busaidy NL, Grubbs EG. The biopsy-proven benign thyroid nodule: is long-term follow-up necessary? J Am Coll Surg. 2013 Jul; 217(1):81-8; discussion 88-9. PMID: 23659946.
      Citations: 10     Fields:    Translation:Humans
    104. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42. PMID: 23185034; PMCID: PMC3537108.
      Citations: 30     Fields:    Translation:Humans
    105. Del Fabbro E, Dev R, Cabanillas ME, Busaidy NL, Rodriguez EC, Bruera E. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer. J Chemother. 2012 Aug; 24(4):221-5. PMID: 23040687; PMCID: PMC4058856.
      Citations: 4     Fields:    Translation:Humans
    106. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 2012 Aug 10; 30(23):2919-28. PMID: 22778315; PMCID: PMC3410405.
      Citations: 82     Fields:    Translation:HumansCells
    107. Morris GS, Landry CL, Grubbs EG, Jimenez C, Busaidy NL, Perrier ND. Greater than age-predicted functional deficits in older patients with primary hyperparathyroidism. Endocr Pract. 2012 Jul-Aug; 18(4):450-5. PMID: 22784831.
      Citations: 4     Fields:    Translation:Humans
    108. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):355-62. PMID: 22658895; PMCID: PMC3974971.
      Citations: 15     Fields:    Translation:Humans
    109. Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res. 2012; 2012:618985. PMID: 22530159; PMCID: PMC3316972.
      Citations: 42     
    110. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res. 2011; 2011:985780. PMID: 22007339; PMCID: PMC3189619.
      Citations: 28     
    111. Khan MI, Habra MA, McCutcheon IE, Devin JK, Busaidy NL, Levine NB, Lindstrom W, Kagan D, Jimenez C, Waguespack SG, Nogueras-Gonz?lez GM. Random postoperative day-3 cortisol concentration as a predictor of hypothalamic-pituitary-adrenal axis integrity after transsphenoidal surgery. Endocr Pract. 2011 Sep-Oct; 17(5):717-26. PMID: 21454228.
      Citations: 1     Fields:    Translation:Humans
    112. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011 Sep 15; 17(18):6052-60. PMID: 21750201; PMCID: PMC3176947.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    113. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer. 2011 Oct 01; 117(19):4381-9. PMID: 21412758; PMCID: PMC3134535.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    114. Landry CS, Grubbs EG, Busaidy NL, Monroe BJ, Staerkel GA, Perrier ND, Edeiken-Monroe BS. Cystic lymph nodes in the lateral neck as indicators of metastatic papillary thyroid cancer. Endocr Pract. 2011 Mar-Apr; 17(2):240-4. PMID: 20713342.
      Citations: 8     Fields:    Translation:Humans
    115. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005. PMID: 21289252; PMCID: PMC3070247.
      Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
    116. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011 Mar; 96(3):717-25. PMID: 21190975.
      Citations: 138     Fields:    Translation:Humans
    117. Ayala-Ramirez M, Habra MA, Busaidy N, Cote G, Rich T, Waguespack S, Jimenez C. A catecholamine crisis on Mount Kilimanjaro: a hypoxia effect? J Travel Med. 2010 Nov-Dec; 17(6):424-6. PMID: 21050326.
      Citations: 2     Fields:    Translation:Humans
    118. Morris GS, Grubbs EG, Hearon CM, Gantela S, Lee JE, Evans DB, Holmes HM, Busaidy NL, Jimenez C, Perrier ND. Parathyroidectomy improves functional capacity in "asymptomatic" older patients with primary hyperparathyroidism: a randomized control trial. Ann Surg. 2010 May; 251(5):832-7. PMID: 20395857.
      Citations: 3     Fields:    Translation:Humans
    119. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010 Jun; 95(6):2588-95. PMID: 20392874.
      Citations: 78     Fields:    Translation:Humans
    120. Williams MD, Suliburk JW, Staerkel GA, Busaidy NL, Clayman GL, Evans DB, Perrier ND. Clinical significance of distinguishing between follicular lesion and follicular neoplasm in thyroid fine-needle aspiration biopsy. Ann Surg Oncol. 2009 Nov; 16(11):3146-53. PMID: 19727961.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    121. Perrier ND, Balachandran D, Wefel JS, Jimenez C, Busaidy N, Morris GS, Dong W, Jackson E, Weaver S, Gantela S, Evans DB, Grubbs EG, Lee JE. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism. Surgery. 2009 Dec; 146(6):1116-22. PMID: 19879613.
      Citations: 20     Fields:    Translation:Humans
    122. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009 Nov; 94(11):4171-9. PMID: 19850694.
      Citations: 19     Fields:    Translation:Humans
    123. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab. 2009 Nov; 94(11):4423-32. PMID: 19820016; PMCID: PMC2775645.
      Citations: 17     Fields:    Translation:Humans
    124. Perrier ND, Edeiken B, Nunez R, Gayed I, Jimenez C, Busaidy N, Potylchansky E, Kee S, Vu T. A novel nomenclature to classify parathyroid adenomas. World J Surg. 2009 Mar; 33(3):412-6. PMID: 19148701.
      Citations: 14     Fields:    Translation:Humans
    125. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009 Apr; 94(4):1310-6. PMID: 19158200.
      Citations: 22     Fields:    Translation:Humans
    126. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008 Jan; 39(1):15-20. PMID: 17949783.
      Citations: 12     Fields:    Translation:HumansCells
    127. Stava CJ, Beck ML, Feng L, Lopez A, Busaidy N, Vassilopoulou-Sellin R. Diabetes mellitus among cancer survivors. J Cancer Surviv. 2007 Jun; 1(2):108-15. PMID: 18648951.
      Citations: 15     Fields:    Translation:Humans
    128. Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006 Jun; 91(6):2201-4. PMID: 16522694.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    129. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006 Mar; 91(3):926-32. PMID: 16384850.
      Citations: 91     Fields:    Translation:Humans
    130. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26. PMID: 15287039.
      Citations: 69     Fields:    Translation:Humans
    131. Shepler TR, Sherman SI, Faustina MM, Busaidy NL, Ahmadi MA, Esmaeli B. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthalmic Plast Reconstr Surg. 2003 Nov; 19(6):479-81. PMID: 14625496.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    132. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemotherapy and Pharmacology. 78:167-171.
    133. Efficacy of the natural clay, calcium aluminosilicate anti-diarrheal, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life. Thyroid. 25:1085-1090.
    134. Oncologic progress for the treatment of parathyroid carcinoma is needed. Journal of Surgical Oncology. 114:708-713.
    135. Clinical Features, Treatments, and Outcomes of Patients with Thymic Carcinoids and Multiple Endocrine Neoplasia Type 1 Syndrome at MD Anderson Cancer Center. Hormones and Cancer. 1-9.
    136. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, (997-1005)). Journal of Clinical Endocrinology and Metabolism. 97:1399.
    137. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 27:81-87.
    138. Bone metastases and skeletal-related events in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 101:4871-4877.
    139. Parathyroid carcinoma and atypical parathyroid neoplasms in MEN1 patients; A clinico-pathologic challenge. The MD Anderson case series and review of the literature. International Journal of Surgery. 31:10-16.
    140. Papillary thyroid carcinoma. 361-381.
    141. Preexisting adrenal masses in patients with adrenocortical carcinoma. Endocrine.
    142. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). Journal of Clinical Endocrinology and Metabolism. 96:2286.
    143. Efficacy and tolerability of vemurafenib in patients with BRAFV600E positive papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 100:E77-E81.
    144. The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatmentwith themammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab. Oncologist. 20:737-741.
    145. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Archives of Dermatological Research. 1-9.
    146. Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma. Oncology (Switzerland). 90:339-346.
    147. Endocrinologic issues. 343-360.
    148. Detection and prognostic significance of circulating tumor cells in patients with metastatic thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 101:4461-4467.
    BUSAIDY's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (435)
    Explore
    _
    Co-Authors (140)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _